Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines

医学 比索洛尔 心绞痛 β受体阻滞剂 心力衰竭 心脏病学 心肌梗塞 血压 重症监护医学 疾病 内科学 原发性高血压
作者
Giuseppe Mancia,Sverre E. Kjeldsen,Reinhold Kreutz,Atul Pathak,Guıdo Grassı,Murray Esler
出处
期刊:Hypertension [Ovid Technologies (Wolters Kluwer)]
卷期号:79 (6): 1153-1166 被引量:69
标识
DOI:10.1161/hypertensionaha.122.19020
摘要

Several hypertension guidelines have removed beta-blockers from their previous position as first-choice drugs for the treatment of hypertension. However, this downgrading may not be justified by available evidence because beta-blockers lower blood pressure as effectively as other major antihypertensive drugs and have solid documentation in preventing cardiovascular complications. Suspected inconveniences of beta-blockers such as increased risk of depression or erectile dysfunction may have been overemphasized, while patients with chronic obstructive pulmonary disease or peripheral artery disease, that is, conditions in which their use was previously restricted, will benefit from beta-blocker therapy. Besides, evidence that from early to late phases, hypertension is accompanied by activation of the sympathetic nervous system makes beta-blockers pathophysiologically an appropriate treatment in hypertension. Beta-blockers have favorable effects on a variety of clinical conditions that may coexist with hypertension, making their use either as specific treatment or as co-treatment potentially common in clinical practice. Guidelines typically limit recommendations on specific beta-blocker use to cardiac conditions including angina pectoris, postmyocardial infarction, or heart failure, with little or no mention of the additional cardiovascular or noncardiovascular conditions in which these drugs may be needed or preferred. In the present narrative review, we focus on multiple additional diseases and conditions that may occur and affect patients with hypertension, often more frequently than people without hypertension, and that may favor the choice of beta-blocker. Notwithstanding, beta-blockers represent an in-homogenous group of drugs and choosing beta-blockers with documented effect in prevention and treatment of disease is important for first choice in guidelines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
金金完成签到,获得积分10
刚刚
假面绅士发布了新的文献求助10
1秒前
jinyu发布了新的文献求助10
1秒前
蔻蔻发布了新的文献求助10
1秒前
成就铸海完成签到,获得积分10
1秒前
2秒前
2秒前
CipherSage应助tt采纳,获得10
2秒前
白开水完成签到,获得积分10
3秒前
滚烫的青春完成签到,获得积分10
3秒前
HY完成签到,获得积分10
4秒前
4秒前
5秒前
小蘑菇应助nannan采纳,获得10
7秒前
7秒前
领导范儿应助smile采纳,获得10
8秒前
小马甲应助smile采纳,获得10
8秒前
孙文远完成签到 ,获得积分10
8秒前
8秒前
9秒前
10秒前
Lucas应助维生素采纳,获得10
10秒前
怡然文龙发布了新的文献求助10
11秒前
Yvonne发布了新的文献求助10
12秒前
充电宝应助美满不平采纳,获得10
12秒前
12秒前
kkk关闭了kkk文献求助
13秒前
风清扬发布了新的文献求助10
13秒前
haoliu完成签到,获得积分10
14秒前
14秒前
14秒前
SciGPT应助chmyt采纳,获得10
14秒前
likexin发布了新的文献求助10
15秒前
快乐不二发布了新的文献求助10
15秒前
张张完成签到,获得积分10
15秒前
16秒前
香蕉觅云应助好的采纳,获得10
16秒前
16秒前
smile完成签到,获得积分10
16秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6024491
求助须知:如何正确求助?哪些是违规求助? 7656750
关于积分的说明 16176485
捐赠科研通 5172859
什么是DOI,文献DOI怎么找? 2767757
邀请新用户注册赠送积分活动 1751236
关于科研通互助平台的介绍 1637502